BNP Paribas Financial Markets’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
FCM
AIM
AVM
NAMA
BNP Paribas Financial Markets's BEAM Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its Beam Therapeutics (BEAM) stake by 52% in Q2 2026, buying an estimated $11.1M and bringing the position to 1,067,883 shares worth $36.6M. The position accounts for 0.01% of the portfolio, ranked #923.
BNP Paribas Financial Markets first reported a position in BEAM in Q4 2024 and has held it in 7 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.
- BNP Paribas Financial Markets held 1,067,883 shares of Beam Therapeutics worth $36.6M as of Q2 2026.
- BNP Paribas Financial Markets bought 367,236 Beam Therapeutics shares in Q2 2026, an estimated $11.1M.
- Beam Therapeutics made up 0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #923 holding.
- BNP Paribas Financial Markets first reported a position in Beam Therapeutics in Q4 2024 and has held it in 7 quarters since.
- 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.